History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines

I Barberis, P Myles, S K Ault, N L Bragazzi, M Martini, I Barberis, P Myles, S K Ault, N L Bragazzi, M Martini

Abstract

Influenza is a highly infectious airborne disease with an important epidemiological and societal burden; annual epidemics and pandemics have occurred since ancient times, causing tens of millions of deaths. A hundred years after this virus was first isolated, influenza vaccines are an important influenza prevention strategy and the preparations used display good safety and tolerability profiles. Innovative tools, such as recombinant technologies and intra-dermal devices, are currently being investigated in order to improve the immunological response. The recurring mutations of influenza strains has prompted the recent introduction of a quadrivalent inactivated vaccine. In the near future, scientific research will strive to produce a long-lasting universal vaccine containing an antigen that will offer protection against all influenza virus strains.

Keywords: History of medicine; Influenza; Vaccination.

References

    1. Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs. J Prev Med Hyg. 2014;55:69–85.
    1. Gasparini R, Amicizia D, Lai PL, Bragazzi NL, Panatto D. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. J Prev Med Hyg. 2014;55:109–129.
    1. Hause BM, Collin EA, Liu R, Huanq B, Shenq Z, Lu W, Wanq D, Nelson EA, Li F. Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. MBio. 2014;5:e00031–e00114.
    1. Collin EA, Sheng Z, Lang Y, Ma W, Hause BM, Li F. Cocirculation of two distinct genetic and antigenic lineages of proposed influenza D virus in cattle. J Virol. 2015;89:1036–1042.
    1. Ducatez MF, Pelletier C, Meyer G. Influenza D virus in cattle, France, 2011-2014. Emerg Infect Dis. 2015;21:368–371.
    1. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263.
    1. Pappas G, Kiriaze IJ, Falagas ME. Insights into infectious disease in the era of Hippocrates. Int J Infect Dis. 2008;12:347–350.
    1. Kohn GC. Encyclopedia of Plague and Pestilence: From Ancient Times to the Present. Infobase Publishing; 2007.
    1. Beveridge WIB. Influenza: The Last Great Plague. London: Heineman Educational Books; 1977.
    1. Wood JM. Influenza. In: Crovari P, Principi N, editors. Le vaccinazioni. Pisa: Pacini Editore; 2000.
    1. Kuszewski K, Brydak L. The epidemiology and history of influenza. Biomed Pharmacoter. 2000;54:188–195.
    1. Gintrac H. Grippe. In: Nouveau dictionnaire de médicine et de chirurgie pratiques, directeur de la redaction: le docteur Jaccoud. 1872, Tome 16, page. 728-753.
    1. Souza CM. The Spanish flu epidemic: a challenge to Bahian medicine. Hist Cienc Saude Manguinhos. 2008;15:945–972.
    1. Potter CW. A history of influenza. J Appl Microbiol. 2001;91:572–579.
    1. Waring J.I. A History of Medicine in South Carolina 1900-70. South Carolina Medical Association; 1971.
    1. Bazin H. Vaccination: a history. France: Editions John Libbey Eurotext Montrouge; 2011.
    1. Renaud F, Hansen W, Freney J. Dictionnaire des precurseurs en bacteriologie. SFM Éditions Eska; 2005. 249 pages.
    1. Craddock S, Giles-Vernick T, Gunn JL. Influenza and Public Health: Learning from Past Pandemics. Earthscan; 2010. - 293 pages.
    1. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet. 1933;2:66–68.
    1. Smith W, Andrewes CH, Stuart Harris CH. The immunization of human volunteers. Special Rep Ser Med Res Council. 1938;228:137–144.
    1. Francis T., Jr Vaccination against influenza. Bull World Health Organ. 1953;8:725–741.
    1. Burnett FM. Influenza virus infection of the chick embryo lung. Br J Exp Pathol. 1940;21:147–153.
    1. Stanley WM. The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J Exp Med. 1945;81:193–218.
    1. Davenport FM. The search for the ideal influenza vaccine. Post-graduate Medical Journal. 1979;55:78–86.
    1. Francis T. Vaccination against influenza. Bull World Health Org. 1953;8:725–741.
    1. Parodi V, Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging. 2011;28:93–106.
    1. Barberis I, Martini M, Iavarone F, Orsi A. Available influenza vaccines: immunization strategies, history and new tools for fighting the disease. J Prev Med Hyg. 2016;57:E41–E46.
    1. Francis T, jr, Salk JE, Pearson HE, Brown PN. Protective effect of vaccination against induced influenza A. J Clin Invest. 1945;24:536–546.
    1. Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza and Other Respiratory Viruses. 2016;10:354–360.
    1. Keitel WA, Neuzil KM, Treanor J. Immunogenicity, efficacy of inactivated/live virus seasonal and pandemic vaccines. Textbook of Influenza. Wiley-Blackwell. 2013:311–326.
    1. WHO Global Influenza Surveillance Network (GISN) [Accessed 20/9/2016].
    1. Oxford J, Gilbert A, Lambkin-Williams R. Influenza vaccines have a short but illustrious history of dedicated science enabling the rapid global production of A/swine (H1N1) vaccine in the current pandemic. In: Rappuoli R, Del Giudice G, editors. Influenza vaccines for the future. Springer Verlag; 2011.
    1. Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14:167–182.
    1. Zaman M, Ashraf S, Dreyer NA, Toovey S. Human infection with avian influenza virus, Pakistan, 2007. Emerg Infect Dis. 2011;17:1056–1059.
    1. Parkman PD, Hopps HE, Rastogi SC, Meyer HM., Jr Summary of clinical trials of influenza virus vaccines for adults. J Infect Dis. 1977;136:722–730.
    1. Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore. 2008;37:510–517.
    1. Crovari P, Alberti M, Alicino C. History and evolution of influenza vaccines. J Prev Med Hyg. 2011;52:91–94.
    1. Gianchecchi E, Trombetta C, Piccirella S, Montomoli E. Evaluating influenza vaccines: progress and perspectives. Future Virology. 2016;11:379–393.
    1. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of cold-adapted recombinant live attenuated influenza vaccines in the U.S.A. and U.S.S.R. Antiviral Res 1982. 1982;1:339–365.
    1. Food and Drug Administration (FDA). FluMist. Prior Approval Supplemental BLA. April 2007. Available at: .[Accessed 20/9/2016].
    1. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12:687–695.
    1. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin Proc. 2010;85:64–76.
    1. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172–180.
    1. Durando P, Iudici R, Alicino C, Alberti M, Florentiis, Ansaldi F, Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin. 2011;7(Suppl):29–40.
    1. Holland D, Booy R, Looze F, Eizenberg P, Mc Donald J, Karrasch J, Mc Keirnan M, Salem H, Mills G, Reid J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198:650–658.
    1. Arnou R, Icardi G, Decker M, Ambrozaitis A, Kazek MP, Weber F, Damme P. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312.
    1. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Hoecke C, Howe BJ, Dubin G. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351:2286–2294.
    1. Bragazzi NL, Orsi A, Ansaldi F, Gasparini R, Icardi G. Fluzone ® Intra-dermal (Intanza® / Istivac® Intra-dermal): an updated overview. Hum Vaccin Immunother. 2016 in press.
    1. Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M, Ansaldi F. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg. 2016;57:E28–E33.
    1. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29:7733–7739.
    1. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox M. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011;29:2272–2278.
    1. Sridhar S. Heterosubtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines. Front Immunol. 2016;7:195–195.
    1. Wiersma LC, Rimmelzwaan GF, Vries RD. Developing universal influenza vaccines: hitting the nail, not just on the head. Vaccines (Basel) 2015;3:239–262.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever